We are conducting routine maintenance on portfolio manager. We'll be back up as soon as possible. Thanks for your patience.

IN BRIEF: Argent Biopharma loss narrows amid investment gain

Argent BioPharma Ltd - Subiaco, Western Australia-based drug discovery company - Pretax loss ...

Alliance News 30 August, 2024 | 5:37PM
Email Form Facebook Twitter LinkedIn RSS

Argent BioPharma Ltd - Subiaco, Western Australia-based drug discovery company - Pretax loss narrows to AUD17.5 million in the financial year ended June 30, from AUD21.1 million a year prior. Revenue from contracts with customers dives to AUD891,083 from AUD3.4 million. Cost of sales decrease to AUD687,386 from AUD1.9 million. Notably, Argent Biopharma reports a gain from a fair value movement on financial instruments of AUD1.3 million, compared to a cost of AUD4.5 million in financial 2023.

Current stock price: 16.15 pence each, closed 13% lower on Friday in London

12-month change: down 23%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Argent Biopharma Ltd 16.50 GBX 0.00 -
Argent Biopharma Ltd 0.29 AUD 3.64 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures